Summary of "유방암, 재발과 항암치료 필요성까지 알 수 있는 검사 #건강톡톡 352회"

Key takeaways from the video (Breast cancer prognosis prediction tests & decision-making)

Help estimate recurrence risk.
Help determine whether additional chemotherapy is needed after surgery.
Aim to avoid chemotherapy when possible, especially if the cancer is likely to be less aggressive.

Uses gene expression analysis from the surgically removed breast cancer tissue.
Combines the expression levels of multiple genes into a single risk score (via an algorithm).
Groups patients into high-risk vs low-risk categories to guide treatment planning.

For hormone receptor–positive and HER2-negative cancers, anti-hormone therapy is typically used.
Prognosis testing helps decide whether chemotherapy adds meaningful benefit beyond hormone therapy.

Oncotype DX
MammaPrint (subtitle shows “Marinet,” likely referring to this)
Onco-Predi (subtitle shows “Onco-Puri,” likely referring to a related test brand/panel)

Results are probabilistic reference, not absolute certainty.
Even if a patient is placed in a lower risk group, chemotherapy may still be recommended in some cases.
Recurrence risk is affected by factors beyond tumor biology (e.g., environmental factors), so 100% matching is impossible.

Most meaningful for:

Less meaningful / not appropriate for:

Imported tests (U.S./Europe) cost about 4–4.5 million KRW.
Domestic (Korean) tests may improve relevance for Korean patients and support better treatment decisions.
The panel notes that some people who should receive testing can be missed, which is part of why testing is emphasized.

Another genetic approach estimates a person’s lifetime risk of developing breast cancer.
Examples mentioned:
- Hope Score
- BRCA1/BRCA2-related risk assessment (if mutations are found)
- BIC (subtitle references around ~80% lifetime risk when applicable; exact interpretation depends on criteria)

Even if results suggest chemotherapy can be avoided, patients may still feel anxiety.
The video emphasizes considering:
- The patient’s overall clinical picture (tumor features, metastasis/pathology)
- Shared decision-making between the medical team and the patient
Takeaway: if evidence supports avoiding chemotherapy, it is generally preferable due to potential long-term side effects.

Analyze surgical tissue to predict recurrence risk and need for anti-cancer treatment.
Representative tests include:
- Onco Type DX, MammaPrint, Onco-Predi (as named in subtitles)
Mainly for:
- ER+ (hormone-positive), HER2−
- Limited/minimal lymph node involvement
Not very meaningful for:
- Triple-negative or HER2+ groups
Used as probabilistic guidance, not a definitive prediction.
General trend by grade:
- Low-grade cancers: anti-cancer treatment may be unnecessary
- High-grade cancers: anti-cancer treatment may be essential

Jeong Jae-hee — Health Talk (host)
Professor Hanbyeol Lee — Department of Breast and Endocrine Surgery, Seoul National University Hospital
Lee An-byeol — Professor of breast endoscopy, Seoul Ya Hospital (appears in subtitles; likely a guest/other presenter)